Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients

Overview

The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment and PSORI-CM01 Granule with moderate to severe psoriasis. Any adverse events related to AD-MSCs infusion will be monitored.The primary outcome is the reduction rate of PASI(Psoriasis Area and Severity Index) and treatment response will be computed from PASI before and after treatment.

Full Title of Study: “Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Patients With Moderate to Severe Psoriasis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 30, 2020

Detailed Description

The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment and PSORI-CM01 Granule with moderate to severe psoriasis. Any adverse events related to AD-MSCs infusion will be monitored.The primary outcome is the reduction rate of PASI(Psoriasis Area and Severity Index) and treatment response will be computed from PASI before and after treatment.

Interventions

  • Drug: Calcipotriol ointment
    • The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
  • Drug: PSORI-CM01 Granule
    • PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
  • Biological: adipose-derived multipotent mesenchymal stem cells
    • AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg

Arms, Groups and Cohorts

  • Experimental: Experimental group
    • AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • PASI score improvement rate
    • Time Frame: 12 weeks (plus or minus 3 days) after treatment
    • PASI score improvement rate = (PASI score before intervention – PASI score after intervention)/PASI score before intervention ×100%

Secondary Measures

  • PASI(Psoriasis Area and Severity Index)
    • Time Frame: 12 weeks (plus or minus 3 days) after treatment
    • The improvement in PASI score from baseline after treatment
  • PASI-50
    • Time Frame: 12 weeks (plus or minus 3 days) after treatment
    • The proportion of patients who achieve at least 50% improvement in PASI score from baseline
  • PASI-75
    • Time Frame: 12 weeks (plus or minus 3 days) after treatment
    • The proportion of patients who achieve at least 75% improvement in PASI score from baseline
  • Pruritus Scores on the Visual Analogue Scale
    • Time Frame: 12 weeks (plus or minus 3 days) after treatment
    • Pruritus was assessed using the Visual Analogue Scales; The Scale scores ranged from 0-10. The higer the scores were, the more itching the patient suffered
  • BSA
    • Time Frame: 12 weeks (plus or minus 3 days) after treatment
    • the Body Surface Area
  • DLQI(Dermatology Life Quality Index)
    • Time Frame: 12 weeks (plus or minus 3 days) after treatment
    • the Dermatology Life Quality Index

Participating in This Clinical Trial

Inclusion Criteria

1. moderate to severe psoriasis vulgaris ( PASI > 10 or BSA >10%)

2. 18 to 65 years old

3. written/signed informed consent

Exclusion Criteria

1. guttate psoriasis, inverse psoriasis or exclusively associated with the face

2. Acute progressive psoriasis, and erythroderma tendency

3. current (or within 1 year) pregnancy or lactation

4. current significant anxiety or depression with the Self-rating Anxiety Scale (SAS) > 50 or the Self-rating Depression Scale (SDS) > 53, or with other psychiatric disorders

5. With history of primary cardiovascular, respiratory, digestive, urinary, endocrinologic and hematologic diseases, which can't be controlled through ordinary treatments. Those who with malignant diseases, infections, electrolyte imbalance, acid-base disturbance. Patients with clinical test results listed below: abnormal serum calcium level ( Ca2+ > 2.9 mmol/L or < 2 mmol/L);AST or ALT 2 times more than normal upper limit; Creatinine and cystatin C more than normal upper limit; Hemoglobin elevates 20g/L more than normal upper limit,or hemoglobin reduction to anemia; Platelet count less than 75.0*10^9/L; White blood cell less than 3.0*10^9/L; Or any other abnormal laboratory test results, assessed by investigators, that are not suitable for this clinical study

6. Patients with malignant tumors, or when they were enrolled with abnormal tumor markers or with other organ dysfunction

7. allergy to anything else ever before;

8. current registration in other clinical trials or participation within a month;

9. topical treatments (i.e. corticosteroids or retinoic acid or Vitamin D analogs ) within 2 weeks; systemic therapy or phototherapy (ultraviolet radiation B,UVB) and psoralen combined with ultraviolet A (PUVA) within 4 weeks; biological therapy within 12 weeks;

10. medical conditions assessed by investigators, that are not suitable for this clinical study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Provider of Information About this Clinical Study
    • Principal Investigator: Chuanjian Lu, Professor – Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Overall Official(s)
    • Chuanjian Lu, PhD, Principal Investigator, Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Overall Contact(s)
    • Chuanjian Lu, PhD, +8620-81887233-31223, luchuanjian888@vip.sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.